MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non–small cell lung cancer (NSCLC).
George R. Blumenschein
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Egbert F. Smit
No relevant relationships to disclose
David Planchard
No relevant relationships to disclose
Dong-Wan Kim
Consultant or Advisory Role - GlaxoSmithKline
Jacques Cadranel
No relevant relationships to disclose
Tommaso De Pas
No relevant relationships to disclose
Frank Dunphy
No relevant relationships to disclose
Katalin Udud
No relevant relationships to disclose
Myung-Ju Ahn
Consultant or Advisory Role - Boehringer Ingelheim (U)
Nasser H. Hanna
No relevant relationships to disclose
Joo-Hang Kim
Research Funding - GlaxoSmithKline
Julien Mazieres
No relevant relationships to disclose
Sang-We Kim
No relevant relationships to disclose
Paul Baas
No relevant relationships to disclose
Erica Rappold
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Suman Redhu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kevin M. Bellew
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Michael R. W. Streit
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Frank S. Wu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Pasi A. Janne
Consultant or Advisory Role - AstraZeneca